

1 Laboratory-confirmed respiratory viral infection triggers for acute myocardial infarction and
2 stroke: systematic review protocol

3 Short title: systematic review protocol of viral triggers for acute cardiovascular events

4

5 Tu Q Nguyen^{1,2*}, Diana Vlasenko^{2,3}, Aishwarya N Shetty^{2,3}, Christopher M Reid^{4,5}, Hazel J
6 Clothier^{1,2,3,6}, Jim P Buttery^{1,2,3,7}

7 ¹ Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia

8 ² Epi-Informatics, Murdoch Childrens Research Institute, Centre for Health Analytics,
9 Melbourne Children's Campus, Melbourne, Victoria, Australia

10 ³ Epi-Informatics group and SAEFVIC, Murdoch Children's Research Institute, 50
11 Flemington Rd, Parkville, Victoria, Australia

12 ⁴ School of Population Health, Curtin University, Perth, Western Australia, Australia

13 ⁵ Centre for Cardiovascular Research and Education in Therapeutics, Monash University,
14 Melbourne, Victoria, Australia

15 ⁶ School of Population and Global Health, The University of Melbourne, Melbourne,
16 Victoria, Australia

17 ⁷ Department of Infectious Diseases, Royal Children's Hospital, Melbourne, Victoria,
18 Australia

19

20 * Corresponding author

21 Email: tun1@student.unimelb.edu.au (TQN)

22 **Abstract**

23 **Background**

24 Cardiovascular disease contributes substantially to global mortality and morbidity.
25 Respiratory tract infections, particularly influenza, may trigger an increase in the short-term
26 risk of acute myocardial infarction and stroke. Recent studies have also linked this risk to
27 other respiratory viruses, including respiratory syncytial virus (RSV) and severe acute
28 respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the pathogen-specific relative
29 contributions, the strength of their associations, and overall public health significance are
30 poorly understood. Assuming causal links, understanding, quantifying, and comparing the
31 effects of different pathogens as triggering factors for acute cardiovascular events is critical
32 to guide future research and prevention. Our aim is to conduct a systematic review to
33 examine the relative effects of laboratory-confirmed respiratory virus infections as triggers
34 for acute myocardial infarction and stroke.

35 **Methods**

36 We will conduct a comprehensive search of Ovid MEDLINE, PubMed, Ovid Embase,
37 Cochrane Library Central Register of Controlled Trials, and Web of Science, from inception
38 to the end of March 2024. We will include the following analytical epidemiological study
39 types: randomised controlled trials, cohort and case-control studies, self-controlled case
40 series, and case-crossover designs. We will not impose restrictions on the date, language,
41 geographical region, or sample size, to minimise the risk of introducing biases. Search results
42 will be screened for eligibility by two independent reviewers, and discrepancies resolved by

43 consensus and/or arbitration by a third reviewer. We will assess the risk of bias among the
44 included studies by adopting the Cochrane Collaboration tools for randomised and non-
45 randomised studies. The overall quality of studies will be assessed using the Grading of
46 Recommendations, Assessment, Development and Evaluations (GRADE) approach. We will
47 examine sources of heterogeneity, and if studies are sufficiently homogeneous, a meta-
48 analysis will be conducted to calculate the pooled effect sizes. Reporting will adhere to the
49 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

50 **Registration**

51 International Prospective Register of Systematic Reviews (PROSPERO) registration number:

52 CRD42024494997

53 **Introduction**

54 **Rationale**

55 Cardiovascular disease (CVD), particularly acute myocardial infarction (AMI) and stroke,
56 remains the world's leading contributor of disease burden and death.[1] Despite progress in
57 age-standardised mortality rates, the prevalence and incidence of acute cardiovascular events
58 is set to rise due to increasing urbanisation, population growth and ageing.[2] Well-
59 established risk factors include air pollution, smoking, poor diet, hypertension, and physical
60 inactivity,[3,4] which explain most but not all of the attributable cardiovascular disease
61 burden. It is thought that precipitating factors such as mental stress, physical exertion, certain
62 drugs and infections may 'trigger' susceptible individuals to experience AMI or stroke.[5]
63 Gaining insight into the role of these factors is crucial for improved risk prediction and
64 prevention.

65

66 Given the prevalence of infections, strong biological plausibility, and apparent reduction in
67 acute cardiovascular outcomes observed in influenza vaccine randomised controlled trials,[6-
68 8] the contribution to the burden of cardiovascular disease may be substantial. To date,
69 reliable data are largely obtained from epidemiological studies focusing on individuals with
70 influenza infection[9]; however, other small-scale studies have described the effects of
71 various bacterial and viral infections on specific cardiovascular endpoints.[10-12] Infections
72 involving the lower and upper respiratory tract are most frequently implicated as triggers for
73 AMI and stroke; attributable respiratory viruses include influenza, respiratory syncytial virus
74 (RSV),[10,11] cytomegalovirus (CMV),[12] and more recently, severe acute respiratory

75 syndrome coronavirus 2 (SARS-CoV-2).[13] Respiratory viruses can infiltrate the lungs
76 through airway epithelial cells, directly stimulating the production of proinflammatory
77 cytokines. The hypothesis is that this triggers systemic inflammation, inducing endothelium
78 damage, atherosclerosis and plaque rupture,[14] increasing the risk of AMI and stroke.[15]
79 The duration of the risk period following respiratory infection is typically brief, lasting from
80 several days to a few months, and gradually diminishes with reduced viral load.[16,17]

81 Given the evidence of a protective relationship between influenza vaccine and cardiovascular
82 disease risk,[18,19] high-quality observational studies of other viral precipitants could pave
83 the way for future trials beyond influenza. However, the comparative pathogen-specific
84 effects of respiratory viruses on the risk of AMI and stroke remain unclear. Modern
85 diagnostic tests, such as increasingly available multiplex respiratory panels, enable the
86 distinction between potentially attributable viruses. Previous systematic reviews and meta-
87 analyses have focused solely on a single viral trigger like influenza or SARS-CoV-2,[20,21]
88 or relied on broad definitions of infection (e.g. symptomatic respiratory tract infection or
89 influenza-like illness),[22] making interpretation challenging as data were not pooled across
90 studies detecting different attributable viruses.[23] In this systematic review, we aim to
91 examine the evidence from studies of respiratory viruses identified by laboratory-
92 confirmatory testing, compare the associations between viral respiratory triggers, and
93 estimate the pooled pathogen-specific effects on acute myocardial infarction and stroke
94 events.

95

96 **Objectives**

97 Our objective is to systematically review the associations between acute myocardial
98 infarction/stroke and laboratory-confirmed respiratory viral infection. This will be addressed
99 through a comprehensive search of analytical epidemiological evidence in humans of any age
100 or geographical region, specifically published studies that capture laboratory-confirmed
101 respiratory viral infections and their effects on acute myocardial infarction or stroke
102 outcomes. A secondary objective is to identify gaps in the literature, assess the certainty of
103 the evidence, and recommend areas for future research.

104

105 **Methods**

106 The systematic review has been registered with the International Prospective Register of
107 Systematic Reviews (PROSPERO). Important protocol amendments will be explained,
108 including the date and reason for the amendment, in the completed published review, in
109 addition to the tracking in PROSPERO.

110 **Eligibility criteria**

111 The eligibility criteria based on the Population, Intervention/Exposure, Comparison,
112 Outcome, Study design, and Timeframe (PICOST) approach, with “intervention” replaced by
113 “exposure”, are as follows:

114 **Population:** Studies involving human participants of any age in any country or region. All
115 healthcare or community settings (e.g. hospital admission, emergency department, ambulance
116 attendances, and primary care consultations) will be considered.

117 **Exposure:** Laboratory-confirmed respiratory viral infection. We will consider viruses that
118 primarily cause illnesses affecting the nose, throat, mouth, and breathing passages, such as
119 common cold or flu-like symptoms. Respiratory viruses include (but are not limited to):
120 influenza, parainfluenza, RSV, human metapneumovirus, rhinovirus, adenovirus, and SARS-
121 CoV-2. Bacteria (including mollicutes) or fungi are excluded. Studies will only be included
122 in which the specific causative microorganism(s) are reported, as detected by confirmatory
123 laboratory methods, including polymerase chain reaction (PCR) and serological tests, but
124 exclude point-of-care testing such as rapid antigen tests. Suspected infection, influenza-like
125 illness, or unspecified respiratory tract infections in the absence of laboratory-confirmed
126 results, are excluded. We will exclude viruses that do not primarily result in respiratory
127 phenotypes, such as human immunodeficiency virus (HIV), viral hepatitis, dengue virus,
128 Ebola virus, and other viral haemorrhagic fevers. Latent or persistent viral exposure, such as
129 human herpesviruses detected solely by serum IgG antibodies, will be excluded.

130 **Comparator:**

131 Eligible studies must include a comparator group that is unexposed, that is, without
132 respiratory infection, negative testing individuals, or non-active/latent infection. This includes
133 individuals with negative laboratory test result(s), an infection-free group in cohort and case-
134 control studies, or unexposed person-time in case-only studies. In randomised controlled
135 trials (RCTs) testing specific anti-infective interventions, such as influenza vaccine studies,
136 data will be treated observationally, that is, the comparator group will be considered
137 regardless of treatment allocation. Before and after (pre–post) COVID-19 pandemic
138 comparators are excluded to ensure all groups have similar chance of exposure to the
139 circulating respiratory virus.

140 **Outcome:** Fatal and non-fatal incidence of AMI or stroke (ischaemic or haemorrhagic),
141 either first or recurrent events. Studies will be included if both or one of these conditions is
142 measured, that is, either AMI or stroke. Diagnosis may be clinical, routinely coded, or self-
143 reported. Patients with composite acute cardiovascular or cerebrovascular outcomes, but not
144 exclusively AMI or stroke, will be excluded. We will exclude transient ischaemic attacks and
145 other neurological or thrombotic conditions in which AMI or stroke is not specifically
146 mentioned, such as unstable angina, cardiac arrest, congestive heart failure or
147 cardiomyopathy, peripheral arterial disease, or venous thromboembolism. Cardiovascular or
148 cerebrovascular inflammatory conditions of infectious origin, such as myocarditis,
149 encephalitis, meningitis, or endocarditis, will be excluded. RCTs capturing adverse events
150 following vaccination and surgical or pharmacological complications will be excluded if
151 AMI or stroke is not the primary outcome. Studies assessing only intermediate outcomes such
152 as inflammatory biomarkers are also excluded.

153 **Study design:** Primary research papers describing RCTs, cohort and case-control studies,
154 self-controlled case series, and case crossover designs. RCTs will be included where there are
155 arm-specific data for the effect of infection for the effect of infection on the risk of incident
156 AMI and/or stroke. Cross-sectional study designs, uncontrolled before-after studies including
157 interrupted time series, ecological studies, case reports, or case series of individual patients,
158 and reviews will be excluded. Studies must report the effect estimates (risk ratio, odds ratio,
159 rate ratio, incidence rate ratio, or hazard ratio) or provide data to calculate an estimate of the
160 effect on the risk of acute myocardial infarction and/or stroke.

161 **Timeframe:** While there are no time restrictions on the risk window or follow-up period
162 used, we will prioritise studies using short-term risk periods (up to 90 days) of laboratory
163 confirmation i.e. primary outcome occurring within the date of specimen collection. Studies

164 with longer risk periods will be assessed for eligibility considering the risk of bias for
165 inclusion. This time window focuses on the cardiovascular triggering effect following viral
166 infection. We will consider contacting corresponding authors to confirm eligibility or to
167 obtain further information where needed.

168

169 No date, country, geographical, language, publication status or minimum sample size
170 restrictions apply. Studies in which the methods are insufficiently described or without
171 extractable results will be excluded. Refinement of the eligibility criteria is expected to be
172 iterative and depends on the search results identified during screening. We will consider
173 contacting authors for clarification or if further information is needed to confirm eligibility.
174 This systematic review will be reported in accordance with the PRISMA guidelines and
175 Meta-analysis of Observational Studies in Epidemiology (MOOSE) statement (if
176 applicable).[24,25] Additionally, the current protocol adheres to the Preferred Reporting
177 Items for Systematic Review Protocols (PRISMA-P) 2015 statement (see S1 File for
178 checklist).[26]

179

180 **Information sources**

181 We will search the following electronic bibliographic databases from their inception until the
182 end of March 2024: MEDLINE (Ovid), Embase (Ovid), PubMed (NLM), Cochrane Central
183 Register of Controlled Trials (Wiley), and Web of Science Core Collection (Clarivate
184 Analytics). The database selection and search strategy were developed in close consultation
185 with an experienced medical/healthcare librarian engaged in the early planning phase. In

186 addition, we will check the reference lists of the included studies (backward citations) and
187 articles that cited the included studies (forward citations) to identify any further relevant
188 papers. Where necessary, investigators will be contacted to request further information about
189 conference abstracts, trial registrations, or unpublished work. A preliminary search of
190 previous systematic reviews on the topic to identify existing or related reviews registered on
191 PROSPERO and via the Cochrane Library has been conducted to avoid duplicating work.
192 Articles cited in previous systematic reviews will be checked to identify any other potentially
193 relevant studies.

194

195 **Search strategy**

196 The search strategy combines thesaurus terms or Medical Subject Headings (MeSH), where
197 available, and free-text synonyms for search concepts based on the PICOST framework (S2
198 File). A search strategy has been designed based on the Population, Exposure, Outcome and
199 Study design elements using Boolean operators (AND, OR) to combine variations of the
200 following search concepts: “Humans”, excluding animal studies; “Laboratory confirmatory
201 tests”, including monoplex or multiplex PCR assays, serology, viral culture and
202 immunofluorescence; “respiratory viruses” including influenza viruses, coronaviruses
203 including SARS-CoV-2, picornaviruses (including enteroviruses), human metapneumovirus,
204 RSV, paramyxoviruses (including parainfluenza viruses), adenoviruses, herpes family viruses
205 (including herpes simplex virus 1 and 2, varicella zoster virus, Epstein-Barr virus and
206 cytomegalovirus) and human bocavirus; “acute myocardial infarction or stroke” including
207 heart attack, cardiovascular death, ischaemic stroke, haemorrhagic stroke; and from analytical
208 epidemiological study designs. Where thesaurus terms or MeSH exist, for example, virus

209 families covering relevant species or subtypes, these have been exploded to include all
210 narrower terms in the tree (if appropriate). The search is limited to RCTs, cohort, case-
211 control, self-controlled case-series and case crossover designs, based on the MEDLINE
212 search filters from BMJ Best Practice for RCTs and epidemiological study designs.[27]. The
213 strategy has been developed initially for MEDLINE via the Ovid interface, then subsequently
214 translated into appropriate search terms for the other databases. The Polyglot Search
215 Translator tool was used to assist with translation across from MEDLINE into the Cochrane
216 Library.[28]

217

218 **Study records**

219 **Data management**

220 Citations retrieved will be uploaded to Covidence, an online software system used to manage
221 systematic reviews and promotes collaboration among authors.[29] Duplicates will be
222 removed using the in-built duplicate feature, and further deduplication by manual review in
223 Covidence. Upon completion of title and abstract screening, full-text articles will be uploaded
224 to Covidence for full-text review. The reference management software EndNote X21
225 (Clarivate Analytics) will be used to manage records outside of Covidence throughout the
226 review.[30]

227 **Selection process**

228 The title/abstract screening process will initially be piloted with at least 50 articles to ensure
229 consistent implementation of the eligibility criteria between reviewers. Following

230 deduplication, the search results will be screened for eligibility by two independent reviewers
231 in two stages: title and abstract screening, followed by a review of the full text. Discrepancies
232 in either of the screening stages will be resolved by consensus and/or arbitration by a third
233 reviewer. Inter-rater reliability will be calculated using the Cohen κ value for both stages of
234 screening. Studies determined to be ineligible will be excluded from the review and reasons
235 for exclusion at the full-text stage reported in accordance with Preferred Reporting Items for
236 Systematic reviews and Meta-analyses (PRISMA).[24] A PRISMA-compliant flow chart will
237 be used to display the selection of articles with reasons for exclusion.

238 **Data collection process**

239 Data will be extracted using a standardised template based on the PICOST framework using
240 Covidence software. A standardised data collection form in Covidence will initially be
241 piloted on at least 50 of the included studies, and changes to the form will be made if
242 required. We will collect data on study populations, settings, exposure and outcome
243 definitions, outcome measures, effect sizes, confidence intervals, and results of significance
244 testing. The authors of the studies will be contacted if missing data are identified during the
245 data extraction phase.

246 We will assess the need for double extraction of results if there is sufficient homogeneity for
247 meta-analysis. If meta-analysis is required, we will use double data extraction (of critical data
248 items required for the interpretation of results) performed independently by two people to
249 minimise errors, and discrepancies will be resolved by discussion. Otherwise, data extraction
250 will be performed by one reviewer and checked for accuracy by a second reviewer.

251

252 **Data items**

253 Data items on the following five domains will be extracted:

254 1. Study characteristics: author(s), publication, year, country, study design, funding source(s)

255 2. Population: characteristics of the study population (e.g., age, sex, country and setting,
256 inclusion and exclusion criteria), sample size, study period, follow-up time (if applicable)

257 3. Exposure: viral respiratory pathogen(s), definition of exposure(s), risk window used, type
258 of laboratory test used, number of exposed subjects

259 4. Comparators: definition of unexposed individuals, number of unexposed subjects,
260 confounders adjusted for

261 5. Outcomes: acute myocardial infarction and/or stroke, outcome definition and method of
262 diagnosis, disease subtype (if applicable), number of subjects with outcome, effective size,
263 95% confidence interval, p-value

264 For studies meeting the inclusion criteria, we will additionally assess mortality outcomes and
265 data among the specific cardiovascular endpoints: ST-elevation myocardial infarction
266 (STEMI) or non-STEMI, and ischaemic or haemorrhagic stroke, if available.

267

268 **Risk of bias in individual studies**

269 Study-level methodological quality assessment will examine the strength of the evidence
270 from individual studies regarding the presence and nature of potential triggering effect(s) of

271 respiratory virus exposure on acute cardiovascular outcomes. We will use the Cochrane
272 Collaboration tools for randomised trials and non-randomised studies, the Cochrane Revised
273 Risk of Bias tool for randomised trials (RoB 2) and the Cochrane Risk of Bias in Non-
274 randomised studies – of Exposures (ROBINS-E) for observational studies to judge overall
275 risk of bias for each individual study based on study methodology.[31] For RCTs, domains
276 will include bias arising from 1) the randomisation process, 2) deviations from intended
277 interventions, 3) missing outcome data, 4) measurement of the outcome and 5) selection of
278 the reported result.[32] For non-randomised studies, the ROBINS-E tool for assessing
279 epidemiological studies of exposure-outcome effects assesses seven domains for bias due to
280 1) confounding, 2) measurement of the exposure, 3) selection of participants into the study or
281 analysis, 4) post-exposure interventions, 5) missing data, 6) measurement of the outcome and
282 7) selection of the reported result.[33]

283 The risk of bias assessment of the studies will be performed independently by two reviewers,
284 and discrepancies will be resolved through discussion to achieve consensus. However, failing
285 agreement, a third reviewer arbitrates. The overall risk of bias judgement will be categorised
286 as ‘low risk of bias’, ‘some concerns’, or ‘high risk of bias’. The results will be synthesised
287 into a narrative summary and incorporated into the primary analysis, stratified by outcome
288 and subgroups, if appropriate. A summary table of domain-level judgments will be produced
289 to show how each study fares.

290

291 **Data synthesis and meta-bias(es)**

292 All syntheses will be categorised according to their primary outcome (acute myocardial
293 infarction or stroke). Study characteristics and measured outcomes will be compiled into
294 summary tables grouped by outcomes and specific viral pathogens. If the studies are
295 sufficiently homogenous by outcome definition and population, we will combine the data
296 statistically in a meta-analysis. A prerequisite is that the outcome definitions and relative
297 effect measures need to match, and that at least three or more studies report the same
298 outcome to trigger a meta-analysis.

299 For studies of the same primary dichotomous outcomes (acute myocardial infarction or
300 stroke), a forest plot visualisation including confidence intervals, Cochrane's Q test for
301 statistical heterogeneity, and I^2 statistic will be used to assess between-study
302 heterogeneity.[34] Where appropriate, meta-analysis will be conducted to calculate pooled
303 effect sizes in a fixed-effect or random-effects model.

304 We will investigate sources of heterogeneity for each primary outcome by:

305 a) Sub-group analysis, and

306 b) Meta-regression, that is, meta-analyses for each subgroup (study design, outcome
307 definition, studies with good/poor control for confounding, effects in older/younger
308 individuals, etc.

309 Factors that may contribute to heterogeneity between studies evaluating the same outcome
310 include: methodological diversity (study design, data source, or setting), study population
311 characteristics (age strata, sex, country, socioeconomic status, and comorbidities), exposure
312 definition (specific virus, laboratory test, or risk window), interventions (vaccinated or

313 unvaccinated), outcome definition (disease, subtype), and diagnosis (clinical diagnosis,
314 administrative data, or self-report).

315 Where meta-analysis is not appropriate, only a qualitative synthesis is presented. Publication
316 bias will be assessed using funnel plots. If sufficient data are available in the included studies,
317 we will synthesise the answers to our research questions by subgroup. All analyses will be
318 performed in R Statistical Software (v4.3.2 or later).[35]

319

320 **Confidence in cumulative evidence**

321 The Grading of Recommendations, Assessment, Development and Evaluation (GRADE)
322 approach will be used to assess the certainty of the evidence for each respiratory virus on
323 each individual outcome, by patient population, across the five domains (Risk of bias,
324 inconsistency, indirectness, imprecision and publication bias) for population-level
325 outcomes.[36] The strength of the evidence will be categorised as ‘low’, ‘moderate’ or ‘high’,
326 with observational studies starting as low-quality evidence, but upgraded to moderate or high
327 quality in the presence of other factors that increase confidence in the result e.g. strong
328 association, evidence of dose response gradient. Owing to the life-threatening, critical nature
329 of our primary outcomes, we consider consistent nonzero relative effects (for example,
330 $RR > 1$) and precise estimates to be important. We will report the GRADE assessment in our
331 results stratified by type of exposure with a row for each important outcome (myocardial
332 infarction, stroke, or specific subtype), and the strength of the evidence will be presented in a
333 ‘Summary of findings’ table. This assessment will enable formal judgement of the overall

334 quality of the evidence included in the review, summarising gaps in the literature, and areas
335 for future research.

336

337 **Ethics and dissemination**

338 This review is ongoing. As this is a systematic review, ethical approval is not required. Upon
339 completion, the results will be submitted to a relevant journal for peer-reviewed publication,
340 presented at scientific conferences in this field. A lay and short summary will be displayed in
341 appropriate reports.

342

343 **Conclusion**

344 Implementing cost-effective policies to avoid premature deaths, disability and unsustainable
345 economic costs attributable to acute myocardial infarction and stroke are a global health
346 priority.[37] There is currently indirect epidemiological evidence regarding the immediate
347 triggering effects of influenza and other respiratory viruses, but the pooled pathogen-specific
348 risk is unknown. Given the co-circulation of respiratory viruses and their increasing ability to
349 prevent and mitigate symptomatic infections, it is important to quantify the relative effects of
350 causative agents, particularly respiratory viruses, in order to evaluate the risk of
351 cardiovascular outcomes. The findings of this systematic review offer value to clinicians as it
352 will provide comprehensive evidence regarding common respiratory virus exposure and risk
353 among high-risk patients. The findings will help to identify candidate pathogens for potential
354 vaccine trials or other preventive therapies in targeted populations. Furthermore, where

355 attributable pathogens have established vaccines, this could be used for potential vaccine
356 probe studies to inform vaccine-preventable cardiovascular burden.[38]

357

358 **Acknowledgements**

359 The authors would like to thank Poh Chua (Librarian, Royal Children’s Hospital Melbourne),
360 whose advice and guidance were of integral importance in planning and designing the search
361 process from the start of the protocol, and Lai-Yang Lee for providing technical expertise in
362 interpreting latent viral diagnostics (Medical Microbiologist, Royal Children's Hospital
363 Melbourne).

364

365 **References**

- 366 1. Institute for Health Metrics and Evaluation (IHME). In: Global Burden of Disease
367 (GBD) Compare [Internet]. GBD 2019 [cited 19 Sep 2023]. Available:
368 <http://vizhub.healthdata.org/gbd-compare>
- 369 2. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al.
370 Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. *J Am Coll*
371 *Cardiol.* 2020;76: 2982–3021. doi:10.1016/j.jacc.2020.11.010
- 372 3. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanus F, et al. Effect of potentially
373 modifiable risk factors associated with myocardial infarction in 52 countries (the
374 INTERHEART study): case-control study. *The Lancet.* 2004;364: 937–952.
375 doi:10.1016/S0140-6736(04)17018-9
- 376 4. O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and
377 regional effects of potentially modifiable risk factors associated with acute stroke in 32
378 countries (INTERSTROKE): a case-control study. *The Lancet.* 2016;388: 761–775.
379 doi:10.1016/S0140-6736(16)30506-2

- 380 5. Schwartz BG, Mayeda GS, Burstein S, Economides C, Kloner RA. When and Why Do
381 Heart Attacks Occur? Cardiovascular Triggers and Their Potential Role. *Hosp Pract.*
382 2010;38: 144–152. doi:10.3810/hp.2010.06.308
- 383 6. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of
384 Myocardial Infarction and Stroke after Acute Infection or Vaccination. *N Engl J Med.*
385 2004;351: 2611–2618. doi:10.1056/NEJMoa041747
- 386 7. Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-Confirmed
387 Respiratory Infections as Predictors of Hospital Admission for Myocardial Infarction
388 and Stroke: Time-Series Analysis of English Data for 2004–2015. *Clin Infect Dis.*
389 2018;67: 8–17. doi:10.1093/cid/cix1144
- 390 8. Omidi F, Zangiabadian M, Shahidi Bonjar AH, Nasiri MJ, Sarmastzadeh T. Influenza
391 vaccination and major cardiovascular risk: a systematic review and meta-analysis of
392 clinical trials studies. *Sci Rep.* 2023;13: 20235. doi:10.1038/s41598-023-47690-9
- 393 9. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et
394 al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. *N Engl*
395 *J Med.* 2018;378: 345–353. doi:10.1056/NEJMoa1702090
- 396 10. Pagliano P, Spera AM, Ascione T, Esposito S. Infections causing stroke or stroke-like
397 syndromes. *Infection.* 2020;48: 323–332. doi:10.1007/s15010-020-01415-6
- 398 11. Ivey KS, Edwards KM, Talbot HK. Respiratory Syncytial Virus and Associations With
399 Cardiovascular Disease in Adults. *J Am Coll Cardiol.* 2018;71: 1574–1583.
400 doi:10.1016/j.jacc.2018.02.013
- 401 12. Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective Study of Herpes
402 Simplex Virus, Cytomegalovirus, and the Risk of Future Myocardial Infarction and
403 Stroke. *Circulation.* 1998;98: 2796–2799. doi:10.1161/01.CIR.98.25.2796
- 404 13. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19.
405 *Nat Med.* 2022;28: 583–590. doi:10.1038/s41591-022-01689-3
- 406 14. Gopal R, Marinelli MA, Alcorn JF. Immune Mechanisms in Cardiovascular Diseases
407 Associated With Viral Infection. *Front Immunol.* 2020;11: 570681.
408 doi:10.3389/fimmu.2020.570681
- 409 15. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial
410 infarction or death from cardiovascular disease: a systematic review. *Lancet Infect Dis.*
411 2009;9: 601–610. doi:10.1016/S1473-3099(09)70233-6
- 412 16. Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-Confirmed
413 Respiratory Infections as Predictors of Hospital Admission for Myocardial Infarction
414 and Stroke: Time-Series Analysis of English Data for 2004–2015. *Clin Infect Dis.*
415 2018;67: 8–17. doi:10.1093/cid/cix1144

- 416 17. Ohland J, Warren-Gash C, Blackburn R, Mølbak K, Valentiner-Branth P, Nielsen J, et
417 al. Acute myocardial infarctions and stroke triggered by laboratory-confirmed
418 respiratory infections in Denmark, 2010 to 2016. *Eurosurveillance*. 2020;25.
419 doi:10.2807/1560-7917.ES.2020.25.17.1900199
- 420 18. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for
421 preventing cardiovascular disease. Cochrane Heart Group, editor. *Cochrane Database*
422 *Syst Rev*. 2015;2015. doi:10.1002/14651858.CD005050.pub3
- 423 19. Fountoulaki K, Tsiodras S, Polyzogopoulou E, Olympios C, Parissis J. Beneficial
424 Effects of Vaccination on Cardiovascular Events: Myocardial Infarction, Stroke, Heart
425 Failure. *Cardiol Int J Cardiovasc Med Surg Pathol Pharmacol*. 2018;141: 98–106.
426 doi:10.1159/000493572
- 427 20. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial
428 infarction or death from cardiovascular disease: a systematic review. *Lancet Infect Dis*.
429 2009;9: 601–610. doi:10.1016/S1473-3099(09)70233-6
- 430 21. Pellicori P, Doolub G, Wong CM, Lee KS, Mangion K, Ahmad M, et al. COVID-19 and
431 its cardiovascular effects: a systematic review of prevalence studies. *Cochrane Database*
432 *Syst Rev*. 2021;2022. doi:10.1002/14651858.CD013879
- 433 22. La Roi-Teeuw HM, Van Smeden M, Bos M, De Wilde SM, Yang B, Rutten FH, et al.
434 Estimated causal effects of common respiratory infections on cardiovascular risk: a
435 meta-analysis. *Open Heart*. 2023;10: e002501. doi:10.1136/openhrt-2023-002501
- 436 23. Davidson JA, Banerjee A, Douglas I, Leyrat C, Pebody R, McDonald HI, et al. Primary
437 prevention of acute cardiovascular events by influenza vaccination: an observational
438 study. *Eur Heart J*. 2023;44: 610–620. doi:10.1093/eurheartj/ehac737
- 439 24. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
440 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*.
441 2021; n71. doi:10.1136/bmj.n71
- 442 25. Stroup DF, Berlin JA. Meta-analysis of Observational Studies in Epidemiology: A
443 Proposal for Reporting. *Meta-analysis of Observational Studies in Epidemiology*
444 (MOOSE) group. *JAMA*. 2000;283: 2008. doi:10.1001/jama.283.15.2008
- 445 26. PRISMA-P Group, Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, et al.
446 Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-
447 P) 2015 statement. *Syst Rev*. 2015;4: 1. doi:10.1186/2046-4053-4-1
- 448 27. British Medical Journal (BMJ) Knowledge Centre. Search strategies. In: *BMJ Best*
449 *Practice* [Internet]. 2023 [cited 29 Dec 2023]. Available:
450 <https://bestpractice.bmj.com/info/toolkit/learn-ebm/study-design-search-filters/>
- 451 28. Clark JM, Sanders S, Carter M, Honeyman D, Cleo G, Auld Y, et al. Improving the
452 translation of search strategies using the Polyglot Search Translator: a randomized
453 controlled trial. *J Med Libr Assoc*. 2020;108. doi:10.5195/jmla.2020.834

- 454 29. Covidence. Melbourne, Australia: Veritas Health Innovation; 2024. Available:
455 www.covidence.org
- 456 30. The EndNote Team. EndNote. Philadelphia, PA: Clarivate; 2024.
- 457 31. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors.
458 Cochrane Handbook for Systematic Reviews of Interventions. version 6.4. Hoboken,
459 NJ: Wiley-Blackwell; 2023. Available: <https://training.cochrane.org/handbook>
- 460 32. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a
461 revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019; 14898.
462 doi:10.1136/bmj.l4898
- 463 33. ROBINS-E Development Group (Higgins J, Morgan R, Rooney A, Taylor K, Thayer K,
464 Silva R, Lemeris C, Akl A, Arroyave W, Bateson T, Berkman N, Demers P, Forastiere
465 F, Glenn B, Hróbjartsson A, Kirrane E, LaKind J, Luben T, Lunn R, McAleenan A,
466 McGuinness L, Meerpohl J, Mehta S, Nachman R, Obbagy J, O'Connor A, Radke E,
467 Savović J, Schubauer-Berigan M, Schwingl P, Schunemann H, Shea B, Steenland K,
468 Stewart T, Straif K, Tilling K, Verbeek V, Vermeulen R, Viswanathan M, Zahm S,
469 Sterne J). Risk Of Bias In Non-randomized Studies - of Exposure (ROBINS-E). 2023.
470 Available: <https://www.riskofbias.info/welcome/robins-e-tool>
- 471 34. Higgins JPT. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327: 557–560.
472 doi:10.1136/bmj.327.7414.557
- 473 35. R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
474 Austria: R Foundation for Statistical Computing; 2021. Available: [https://www.R-](https://www.R-project.org/)
475 [project.org/](https://www.R-project.org/)
- 476 36. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1.
477 Introduction—GRADE evidence profiles and summary of findings tables. *J Clin*
478 *Epidemiol*. 2011;64: 383–394. doi:10.1016/j.jclinepi.2010.04.026
- 479 37. UN DESA. The Sustainable Development Goals Report 2023: Special Edition - July
480 2023. New York, USA: UN DESA; 2023. Available:
481 <https://unstats.un.org/sdgs/report/2023/>
- 482 38. Feikin DR, Scott JAG, Gessner BD. Use of vaccines as probes to define disease burden.
483 *The Lancet*. 2014;383: 1762–1770. doi:10.1016/S0140-6736(13)61682-7
- 484

485 **Supporting information**

486 **S1 File. PRISMA-P checklist.** Preferred Reporting Items for Systematic review and Meta-
487 analysis Protocols (PRISMA-P) checklist

488 **S2 File. Search strategy.** Search strategy for Ovid MEDLINE, Ovid Embase, PubMed,
489 Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science